Business
Calidi is a clinical-stage biotech developing oncolytic virus therapies, including stem-cell loaded approaches intended to target metastatic cancer sites.
Calidi stayed pre-revenue; insider buys offset cash-burn caution.
The read at a glance✓ Audited against SEC data
- Business mix — Oncolytic cancer platformNote
- Revenue — FY2025 revenue N/AWatch
- Net loss — $19.9M, narrowerOK
- Cash burn — Operating cash outflow worsenedWatch
- Equity — $3.8M, +145.0%OK
- Altman/Beneish/EQ — Limited screen coverageWatch
- Insiders — 4 purchases / 1 saleOK
Leadership changes
From Calidi Biotherapeutics, Inc.'s own filings, the day they're filed.
- Scott Leftwich · director · appointmenteff. 2026-04-01
- George Peoples · director · appointmenteff. 2024-07-01
- Thomas Vecchiolla · director · departureeff. 2024-01-01
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-06-23
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Calidi Biotherapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.